BNP Paribas Financial Markets’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-171,397
| Closed | -$273K | – | 4261 |
|
|
2024
Q1 | $273K | Sell |
171,397
-49,259
| -22% | -$73.1K | ﹤0.01% | 3143 |
|
|
2023
Q4 | $190K | Buy |
220,656
+133,999
| +155% | +$118K | ﹤0.01% | 3242 |
|
|
2023
Q3 | $92.7K | Buy |
86,657
+46,350
| +115% | +$95.9K | ﹤0.01% | 3346 |
|
|
2023
Q2 | $104K | Sell |
40,307
-1,516
| -4% | -$5.41K | ﹤0.01% | 3242 |
|
|
2023
Q1 | $171K | Buy |
41,823
+13,808
| +49% | +$63.8K | ﹤0.01% | 3197 |
|
|
2022
Q4 | $141K | Buy |
28,015
+10,923
| +64% | +$68.5K | ﹤0.01% | 3128 |
|
|
2022
Q3 | $224K | Buy |
17,092
+2,014
| +13% | +$30.5K | ﹤0.01% | 3442 |
|
|
2022
Q2 | $193K | Sell |
15,078
-6,934
| -32% | -$96K | ﹤0.01% | 3102 |
|
|
2022
Q1 | $336K | Sell |
22,012
-4,781
| -18% | -$74.6K | ﹤0.01% | 2940 |
|
|
2021
Q4 | $475K | Buy |
26,793
+19,124
| +249% | +$367K | ﹤0.01% | 3032 |
|
|
2021
Q3 | $161K | Buy |
7,669
+4,354
| +131% | +$95.8K | ﹤0.01% | 3125 |
|
|
2021
Q2 | $65.4K | Sell |
3,315
-119
| -3% | -$2.79K | ﹤0.01% | 3171 |
|
|
2021
Q1 | $99.8K | Sell |
3,434
-1,123
| -25% | -$31.4K | ﹤0.01% | 3355 |
|
|
2020
Q4 | $138K | Sell |
4,557
-1,709
| -27% | -$37.4K | ﹤0.01% | 3063 |
|
|
2020
Q3 | $99.7K | Buy |
6,266
+5,138
| +455% | +$93.7K | ﹤0.01% | 3118 |
|
|
2020
Q2 | $22.3K | Sell |
1,128
-6,412
| -85% | -$123K | ﹤0.01% | 3352 |
|
|
2020
Q1 | $93K | Buy |
7,540
+4,702
| +166% | +$76.8K | ﹤0.01% | 3247 |
|
|
2019
Q4 | $52.5K | Buy |
2,838
+2,511
| +768% | +$36.7K | ﹤0.01% | 3627 |
|
|
2019
Q3 | $4.53K | Buy |
327
+295
| +922% | +$4.43K | ﹤0.01% | 4283 |
|
|
2019
Q2 | $468 | Buy |
+32
| New | +$468 | ﹤0.01% | 4409 |
|
BNP Paribas Financial Markets's NGM Position: Q2 2024 in Review
BNP Paribas Financial Markets sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 171,397 shares — an estimated $273K sold.
BNP Paribas Financial Markets first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $475K in Q4 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- BNP Paribas Financial Markets reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- BNP Paribas Financial Markets sold 171,397 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $273K.
- BNP Paribas Financial Markets first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- BNP Paribas Financial Markets's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $475K in Q4 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2024, filed 13 Aug 2024.